Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivani MedicalSTU:U5P -6.40%35 FCF Yield % is -21.76 as of Sep. 09, 2026. GuruFocus rates STU:U5P with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,406 Biotechnology companies, Vivani Medical ranks worse than 68.21% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Vivani Medical FCF Yield % Related Terms
Vivani Medical FCF Yield % Historical Data
* Premium members only.
The historical data trend for Vivani Medical's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:U5P vs BDTX, VTVT, TLSA: FCF Yield % Comparison
For the Biotechnology subindustry, Vivani Medical's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivani Medical FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivani Medical's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Vivani Medical's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivani Medical (STU:U5P) has a FCF Yield % of -21.76 as of Sep. 09, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vivani Medical and its competitors. According to the industry distribution chart, Vivani Medical ranks #959 out of 1406 companies in the Biotechnology industry, placing it in the top 68.2%.
Is Vivani Medical's FCF Yield % too high?
Vivani Medical's current FCF Yield % is -21.76. Based on the distribution chart, Vivani Medical ranks #959 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vivani Medical has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Vivani Medical's FCF Yield % compare to BDTX and VTVT?
According to the Biotechnology industry distribution chart, Vivani Medical ranks #959 out of 1406 companies for FCF Yield %. This places Vivani Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vivani Medical and its competitors. Vivani Medical's current FCF Yield % is -21.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivani Medical stock overvalued right now?
Vivani Medical (STU:U5P) has a current FCF Yield % of -21.76. The current FCF Yield % is -21.76. Vivani Medical's overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Vivani Medical (STU:U5P), the current FCF Yield % is -21.76 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
35GF Score
Get the complete analysis for STU:U5P
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:U5P has been successfully added to your 
